It has been recently reported that an orally bioavailable dual inhibitor of ATM and DNA-PKcs kinases synergized with PARP inhibitors in BRCA1/2-deficient models, including UWB1.289, a BRCA1-mutant human ovarian cancer cell line [39]. Here, PARP1 is linked to ovarian cancer.